CTIS2023-506703-26-00招募中1 期
Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial - IJB-SHAPERS-ODN-013
Institut Jules Bordet0 个研究点目标入组 264 人开始时间: 2023年10月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65 至 65+（—）
- 性别
- All
入选标准
- •Age = 70 years old, Signed Informed Consent form (ICF) obtained prior to any study related procedure., Male subjects with partners of childbearing potential must agree to use condom during the course of this study and for at least 6 months after the last administration of study drugs., ECOG performance status (PS): =1 if age > 75 years old, =2 if age = 75 years old, Histologically or cytologically confirmed adenocarcinoma of the rectum, Distal border of the tumour below the peritoneal reflection and within 15 cm of the anal verge, Operable stage III or high-risk stage II rectal cancer (high-risk tumours defined as those having =1 of the following features: T4, mesorectal fascia (MRF) involvement/threatening [i.e.,tumour within 1 mm of the MRF], extramural venous invasion). Patient with involvement of lateral pelvic lymph nodes are also eligible., Adequate bone marrow function as defined below: -Absolute neutrophil count =1,500/µL -Haemoglobin =9 g/dL -Platelets =100,000/µL, Adequate liver function as defined below: -Serum total bilirubin =1.5 x ULN. In case of known Gilbert’s syndrome <3xUNL is allowed -AST (SGOT) and ALT (SGPT) =2.5 x ULN -Alkaline phosphatase =2.5 x ULN, Adequate renal function as defined by estimated glomerular filtration rate (GFR) =30 mL/min/1.73m² (according to the CKD-EPI 2021 equation), Absence of clinical conditions that in the opinion of the investigator, would contraindicate neoadjuvant therapy and/or surgery.
排除标准
- •Extensive growth into cranial part of the sacrum (above S2/3 junction) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is achieved., Known dihydropyrimidine dehydrogenase (DPD) deficiency., Any previous treatment for rectal cancer, Presence of metastatic disease or recurrent rectal tumour., Presence of grade =2 peripheral neuropathy according to the Common Toxicity Criteria for Adverse Events (CTCAE) v.5.0., Significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator’s opinion, may interfere with completion of the study., Any contraindication to pelvic irradiation as evaluated by the investigator., Known hypersensitivity reactions to the study drugs or to any excipients, premedications or non-investigational medicinal products or concomitant medications., Any investigational anti-cancer therapy other than the protocol specified therapies (participation in other prospective studies which do not imply any specific intervention may be allowed after discussion with the Study Chair)., Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment., Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (grade III or IV as classified by the New York Heart Association), or serious cardiac arrhythmia requiring medication medication within the past 6 months.
研究者
相似试验
尚未招募
1 期
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRCMetastatic Colorectal CancerMetastatic Colorectal AdenocarcinomaCRCNCT06195670Zhejiang Cancer Hospital220
招募中
2 期
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRectal CancerLocally AdvancedNCT05576480Ruijin Hospital55
进行中（未招募）
1 期
ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patientsA randomized phase III trial of the German Rectal Cancer Study Groupocally advanced rectal cancer (UICC stage II and III)MedDRA version: 21.0Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000876-14-DEniversity Hospital Frankfurt, Goethe University702
已完成
3 期
Short-term radiotherapy versus chemoradiotherapy followed by consolidating chemotherapy and selective organ preservation for Patients with MRI-defined intermediate and high riskC20Malignant neoplasm of rectumDRKS00020770Klinik für Strahlentherapie Universitätsklinikum Frankfurt/M702
招募中
2 期
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal AdenocarcinomaRectal AdenocarcinomaNCT06266832Sir Run Run Shaw Hospital30